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ABSTRACT
Intravenous drug administration in Neonatal Intensive Care Unit is critical because of poor venous access, polymedication, fluid restriction, and low 
infusion rate. Since parenteral nutrition (PN) is infused intravenously, it is often considered as a vehicle for medication administration. Medications 
may be added to PN formulations in an effort to decrease fluid requirements, reduce the need for Y-site injections, reduce the possibility of line 
contamination due to manipulation, and decrease labor time required for drug administration. Risk is further increased by inadequate information on 
the physicochemical compatibility of drugs.
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INTRODUCTION
Malnutrition is a state in which a deficiency of nutrients such as energy, 
protein, vitamins and minerals causes measurable adverse effects on 
body composition, function or clinical outcome. Malnutrition is both 
a cause and a consequence of ill health. It is common and increases 
a patient’s vulnerability to disease. Methods to improve or maintain 
nutritional intake are known as nutrition support. These include oral 
nutrition support - for example, fortified food, additional snacks and/or 
sip feeds, enteral tube feeding - the delivery of a nutritionally complete 
feed directly into the gut via a tube and parenteral nutrition (PN) - 
the delivery of nutrition intravenously. These methods can improve 
outcomes, but decisions on the most effective and safe methods are 
complex [1].
Ever since the late 1960s, when Wilmore and Dudrick first published 
their research on central venous alimentation, which promoted growth 
in an infant [2], PN has been an important adjunctive therapy for 
many patients with catabolic medical conditions including the elderly. 
Whether these patients are receiving this therapy in an acute-care 
setting, a long-term care setting, or at home, pharmacist should be 
knowledgeable about the therapy and be able to assess its effectiveness 
as well as prevent complications associated with total PN [3].
Over the last four decades, PN has become an important primary 
(e.g., intestinal failure) and adjunctive therapy of disease states. PN 
is commonly used in such condition as severe pancreatitis, short-
bowel syndrome, inflammatory bowel disease exacerbations, and 
gastrointestinal (GI) fistulae, as well as in critically ill patients, 
infants with very low birth weight, and patients with cancer receiving 
hematopoietic cell transplantation [4].
PN INPEDIATRIC
PN is used to treat children that cannot be fully fed by oral or enteral 
route, for example, due to severe intestinal failure [7]. Intestinal 
failure occurs when the GI tract is unable to ingest, digest and absorb 
sufficient macronutrients and/or water and electrolytes to maintain 
health and growth. Children differ from adults in that their food intake 
must provide sufficient nutrients not only for the maintenance of body 
tissues but also for growth. This is particularly true in infancy and 
during adolescence when children grow extremely rapidly. At these 
times, children are particularly sensitive to energy restriction because 
of high basal and anabolic requirements [8,9].
The ability to provide sufficient nutrients parenterally to sustain 
growth in infants and children suffering from intestinal failure or severe 
functional intestinal immaturity represents one of the most important 
therapeutic advances in pediatrics over the last three decades. 
Improvements in techniques for artificial nutritional support now 
ensure that children in whom digestion and absorption are inadequate 
or who are unable to eat normally no longer need to suffer from the 
serious consequences of malnutrition including death [10,11].
PN for newborn premature infants
PN is the intravenous (IV) infusion of all nutrients necessary for 
metabolic requirements and growth. PN refers to the IV infusion 
of nutrients by peripheral or central vein. Enteral nutrition (EN) 
is provided by oral or gavage feedings. PN is commonly indicated 
in neonates experiencing congenital malformation of the GI tract, 
gastroschisis, meconium and paralytic ileus, short-bowel syndrome, 
necrotizing enterocolitis, respiratory distress syndrome, extreme 
prematurity, sepsis, and malabsorption. The ability to provide EN and 
PN over the last four decades has significantly improved the overall 
survival of newborns when other options of adequate nutritional 
support were not possible [12].
The goal of PN is to initially provide sufficient nutrients to prevent 
negative energy and nitrogen balance and essential fatty acid deficiency 
and support normal rates of intrauterine growth of appropriate 
composition without increased significant morbidity. Fear of toxicity 
and metabolic imbalance has alerted clinicians to use PN with caution, 
especially in the sickest and most premature infants. An increasing 
number of practitioners appreciate that this cautionary management has 
resulted in suboptimal nutrition intake of these infants. Practitioners have 
speculated that this cautionary practice contributed in part to national 
growth failure outcome statistics published of infants extremely low in 
birth weight (ELBW; <1000 g) and appropriate for gestational age (AGA; 
weight ≥10th percentile norm) born from 1995 to 1996. When assessed at 
discharge (≈36 weeks’ corrected age) 99% of these infants had significant 
growth failure with weights less than the 10th percentile compared with 
intrauterine growth standards [12,13]. Longer-term statistics indicate 
that a significant percentage of infants born very low in birth weight 
(VLBW; <1500 g) may suffer substantial neurodevelopmental deficits in 
part attributable to inadequate nutritional support in the neonatal period 
[14]. In more recent years, the earlier introduction and more aggressive 
advancement of PN were shown to be safe and effective, even in the 
smallest and most immature infants [15-19].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Timely intervention with PN begins with the provision of glucose 
as soon as possible after birth with amino acids within the first 12 
hrs, IV fat within the first 24-48 hrs, and trophic feeding within the 
first 24 hrs [20]. The optimal use of routine PN for nutritional support 
of  LBW and VLBW infants may influence short-term outcomes such as 
lower propensity to infection and shortened hospital stay, as well as 
longer-term outcomes such as decreased growth deficits, [56] improved 
neurodevelopment, and overall morbidity [21-23]. Indications that are 
generally recognized as those that necessitate PN for newborns are 
listed in Table 1.
Components of PN solutions
PN provides some or all nutrients of basal metabolism and growth 
for fluid, energy, macronutrients (protein, carbohydrate, and fat), 
and micronutrients (electrolytes, major minerals, trace minerals, and 
vitamins) [24-31]. Recommended intakes for premature and term 
neonatesare summarized in Table 2.
An overview of fluid, macronutrient, and micronutrient 
recommendations follows.
Fluid
On day one of life, maintenance fluids are met with a range between 
80 and 140 mL/kg/d if the environment of the baby increases 
insensible water losses and 60-100 mL/kg/d in environments with 
increased humidity. Thereafter, fluid volume is advanced as tolerated 
to 120-180 mL/kg/d. Maximal fluid volume varies with individual 
management [25].
Macronutrients
Carbohydrate (dextrose) and fat (lipid emulsions) provide the energy 
needed to meet the demands of the circulatory, respiratory, neurological, 
and muscular systems, and when provided in adequate amounts, spare 
protein (amino acids) to support cell maturation, remodeling, growth, 
activity of enzymes, and transport proteins for all body organs. Energy 
needs may be increased with infection, chronic lung disease, healing, 
growth, and in babies who have experienced intrauterine growth 
restriction. Energy needs may be decreased with sedation, mechanical 
ventilation, and after tracheostomy placement.
Initiation and advancements of macronutrients in PN solutions
The use of PN is suggested to support all ill and premature babies <1500 g 
that cannot sustain at least ~60 kcal/kg/denterally and initiation is 
recommended during the first 24 hrs of life to avoid excessive protein 
losses. The premature infant who is not growing, not septic, and not 
unduly stressed requires an energy intake of about 50 kcal/kg/d for 
resting energy expenditure, activity, and occasional cold stress [33-37], 
with as little as ~1-1.5 g protein/kg/d to preserve endogenous protein 
stores [17,38,39]. At least 60 kcal/kg/d is thought to meet energy 
requirements during acute sepsis [40]. Provision of >70 kcal/kg/d and 
2.7-3.5 g protein/kg/d has been demonstrated to support growth and 
positive nitrogen balance in preterm infants [36].
Carbohydrate
Carbohydrate is delivered in 2.5-70% dextrose solutions that 
provide 3.4 kcal/g. Glucose is the energy source for all cells and 
is essential for the central nervous system, erythrocytes, and 
other tissues. To ensure a stressed premature infant receives an 
adequate but not excessive amount of glucose, the amount of 
carbohydrate delivered in the form of dextrose is commonly initiated 
at the endogenous hepatic glucose production and utilization rate 
of 4-6 mg/kg/minutes [41]; 8-10 mg/kg/minutes in ELBW infants 
provides 40-50 kcal/kg/d and preserves carbohydrate stores [32].
Frequently smaller, more unstable premature infants develop 
hyperglycemia due to decreased insulin production and insulin 
resistance. Glucose infusion rates (GIRs) for these babies may need to 
be limited to 4 mg/kg/minutes or less, while larger preterm infants or 
term infants can often tolerate up to 8 mg/kg/minutes initially [34,42]. 
Once the GIR supports acceptable serum glucose values, it is advanced 
in a gradual, stepwise fashion (0.5-1 mg/kg/minute) to a suggested 
maximum glucose oxidative rate for neonates of 12-13 mg/kg/minutes 
to support growth and maintained there unless serum glucose values 
change significantly [43,44].
In most situations, a glucose concentration >12.5% is not necessary [34]. 
However, a higher glucose concentration may be needed when fluid 
intake is severely restricted or when the amounts of protein and/or fat 
are limited [34]. Excessive carbohydrate delivery above the amount that 
can be oxidized for energy and glycogen storage will lead to an increase 
in basal metabolic rate [45], fat deposition, cholestasis [46], hepatic 
steatosis [47], or overfeeding as described by the provision of energy in 
excess of needs for normal growth [47]. GIR >26 mg glucose/kg/minutes 
may contribute to infiltrates of fat in the liver [48].
Practically, a premature infant who is able to tolerate a fluid volume of 
140-150 mL/kg/d will meet macronutrient needs for growth if provided 
a dextrose concentration of 10% (~10-10.5 mg glucose/kg/minutes) or 
12.5% (~12-13 mg glucose/kg/minutes); if the protein and fat intakes 
are both at least 3 g/kg/d, the solutions will approximate 80-95 and 
100-105 kcal/kg/d, respectively. Additional dextrose delivery from IV 
medication needs to be taken into account when calculating the GIR for 
individual babies [49,66].
To optimize the amount of fluid available to provide nutrition to the 
small premature baby while trying to maintain a euglycemic state, it 
may be necessary to double-concentrate the continuous infusions that 
deliver medications and run them at lower rates. Consultation with the 
pharmacist can ensure that these lower medication infusion rates are the 
adequate for optimum clinical effectiveness of the IV drug. If further fluid 
restriction or dextrose limitation is necessary, other options to optimize 
the delivery of glucose are to minimize the amount of fluids delivered 
with IV medications or needed to keep a line patent and decrease the 
dextrose concentration of the IV medication solution so that slightly 
more dextrose can be delivered from the PN solution and/or increase 
the dextrose concentration of the IV medication solution to equal that of 
the PN solution while ensuring glucose tolerance [12].
Protein
Protein is delivered as free amino acids in solutions developed 
specifically for pediatric patients with an amino acid profile that is 
higher in amounts of amino acids believed to be conditionally essential 
for premature infants (aspartate, glutamate, taurine, and tyrosine) and 
with lesser amounts of glycine compared with adult solutions. Cysteine 
Table 1: Indications for PN support and route of administration 
for newborn infants who require intensive care
Route of PN 
administration
Indication for PN











Line access in infants extremely low
In birth weight<1000 g
PN: Parenteral nutrition, GI: Gastrointestinal
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Table 2: Usual daily requirements of nutrients in PN solutions for preterm and term infants
Nutrient additive Usual daily requirements in PN
Neonatal amino acid For maintenance:
1.5-2.5 g/kg/d
For ELBW infants, begin at a minimum of 1.5 g/kg/d as Soon as possible.
Goals for growth:
3.5 g/kg/d for<1000 g
3.0 g/kg/d for 1000-2500 g
2.5 g/kg/d for>2500 g
4.0 g/kg/d for some infants with
greater needs
Cysteine hydrochloride 40 mg/g of amino acids (120 mg/kg maximum)
Refer to acetate guidelines for ELBW infants (see below under excess anions)
Dextrose For maintenance:
4-6 mg/kg/min (endogenous hepatic glucose
production)
8-10 mg/kg/min (preserves carbohydrate stores)32




Lipid (20% emulsion from 100% soy oil) 0.5-4.0 g/kg/d; begin 0.5-1.0 g/kg/d and advance by 0.5-1.0 g/kg/d
Essential fatty acids met with 1.0 g/kg/d and at least 80 kcal/kg/d
Delivered as a component to the amino acid–glucose solution (admixture) or as a separate 
solution





Dextrose (40-60%), lipid (40-50%), protein (10-15%)
Carnitine 2-10 mg/kg/d not to exceed 50 mg/kg/d69
Heparin 1 unit/mL not to exceed 137 units/d
0.5 unit/mL for ELBW infants when volume exceeds 150 mL/kg/d
Sodium (Na) as chloride or phosphate 2-4 mEq/kg/d
Positive nitrogen balance is critical
for growth; ELBW infants may
require increased intake
Potassium (K) as chloride or phosphat 2-4 mEq/kg/d
Consider omitting in ELBW infants
until renal sufficiency is well
established
Chloride (Cl) 2-4 mEq/kg/d





Usually provide electrolytes as acetate always use 
acetate if adding cysteine hydrochloride for ELBW
Calcium (Ca) as gluconate 1-3 mEq/kg/d for maintenance
3-4.5 mEq/kg/d for growth (see text for solubility limits)
Should be administered through a central line rather than a peripheral line in premature infants
Phosphorus (P) as sodium
or potassium phosphate
1.3 mmol/kg/d for maintenance [29]
1.5-2.0 mmol/kg/d for growth
Magnesium (Mg) 0.25-1.0 mEq/kg/d
Begin ELBW infants at low end
Increased needs for infants with
ostomy losses
Vitamins as MVI-pediatric Premature: 2 ml/kg/day to a maximum of 5 mL/d
Term: 5 mL/d
Zinc (Zn) as sulfate or in PTE solution 400 µg/kg/d: Preterm infants and all infants with gastrointestinal losses
250 µg/kg/d: Term infants 0-3 months
100 µg/kg/d: Term infants>3 months and all infants with long-term PN
Copper (as sulfate or in PTE) Withhold during the first 2 weeks of PN, then initiate at 20 µg/kg/day
Decrease amount or withhold with complication of obstructive jaundice
Selenium in PTE Withhold during the first 2 weeks of PN
Decrease amount or withhold with complication of renal dysfunction




Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 54-64
 Oktavia et al. 
is also considered as conditionally essential in premature infants due 
to a theoretical insufficiency of enzymatic activity for the conversion 
of methionine to cysteine. Cysteine is not contained in amino acid 
solutions because of problems with long-term stability and addition 
as aseparate solution as the solution is prepared is compatible and 
is needed to meet recommendations [50]. Cysteine hydrochloride 
supplements may cause metabolic acidosis, and therefore, PN solutions 
may need to be buffered with acetate [12].
Other special amino acid solutions designed specifically for patients 
with hepatic failure, renal disease, and higher protein needs have not 
been studied in infants and therefore are not recommended for infants. 
Amino acid profiles of these solutions are summarized elsewhere [51]. 
Amino acid solutions provide 4.0 kcal/g of protein. In neonates, protein 
accretion is thought to more adequately reflect nutritional status than 
weight gain [52]. Studies in preterm babies who receive PN suggest that 
protein accretion occurs by amino acid stimulation of protein synthesis 
rather than by suppression of protein break down [17,53].
Protein requirements for the neonate tend to be inversely related to 
gestational age and size due to more rapid growth rates and greater 
protein losses in the smaller, more premature infants [54,55]. The 
early provision of protein is critical to attain positive nitrogen balance 
and accretion, as premature babies lose ~1% of their protein stores 
daily  [54,55]. The studies suggest the provision of at least 1 g/kg/d 
of amin acids can decrease catabolism [16,38,56]. ELBW infants can 
generally receive 2 g/kg/d of amino acids on the 1st day of life [16,57].
A classic study by Zlotkin et al. [36] suggests a protein goal of at least 
2.7-3.5 g/kg/d with the adequate energy of >70 nonprotein kcal/kg/d 
to approximate in utero nitrogen accretion. Studies show that early 
and aggressive provision of 3 g protein/kg/d and adequate nonprotein 
energy within the first few days of life is safe and effective at providing 
protein to meet accretion needs and facilitate intrauterine growth 
rates [15,34]. Protein requirements may be increased to counter 
catabolic or excretory losses in clinical conditions such as postoperative 
wound-healing, chronic lung disease treated with steroids, lymphatic 
injury with a sustained chyle leak, and/or during sustained periods 
when infants require limited or withheld enteral feeding or higher 
amounts of protein for catch-up growth [43,56-59].
To date, there is no evidence from randomized trials to support the routine 
use of parenteral or enteral glutamine supplementation in preterm 
infants [59,60]. Studies in critically ill adults suggest that glutamine 
supplemented amino acid solutions may reduce mortality, improve 
nitrogen balance, and reduce the incidence of clinical infection [47].
Fat
Fat is delivered as lipid emulsions of neutral triglycerides (TG), 
primarily polyunsaturated fatty acids (PUFAs) that are essential for 
normal growth and development, retinal development and function, 
brain development, and cell structure and function. Lipid emulsions 
provide a concentrated source of energy, 10 kcal/g of fat that enables the 
provision of nutrient intakes to premature infants within limited fluid 
volumes to achieve in utero rates of growth. Adequate administration 
of lipids prevents essential fatty acid deficiency, promotes positive 
nitrogen balance, and optimizes energy utilization. Solutions with 
100% soy oil provide 54% of energy as linoleic acid and 8% as linolenic 
acid, whereas the 50% soy and 50% safflower mixture provides 
66% of energy as linoleic acid and only 4.2% of energy as linolenic 
acid. Recommendations to prevent essential fatty acid deficiency in 
premature infants are to provide at least 80 kcal/kg/d, which will limit 
utilization of stored fat for energy and thus preserve docosahexaenoic 
acid and arachidonic acid stores [61,62]. An intake of linoleic acid is 
recommended at 4-5% of total calories and that of linolenic acid at 1% 
of total calories [61,63].
Based on a minimal intake of 80 kcal/kg, a fat intake of 0.6-0.8 g fat/kg 
will meet linoleic acid recommendations and 1.0 g fat/kg will meet 
linolenic acid recommendations from a solution that is 100% soy. 
Because the 50% soy and 50% safflower mixture provides less linolenic 
acid, the amount required to meet recommendations is 2.0 g fat/kg. 
Lipid emulsions are available as 10 and 20% solutions; 20% solutions 
require less fluid volume and provide a lower phospholipid-to-TG ratio 
and therefore are recommended for premature infants. Lipid solutions 
also available with shorter chain and monounsaturated fats from olive 
oil and medium chain TG (MCT) oil. When compared with the longer 
chain TG solutions, those that contain MCT and olive oil provide a 
greater vitamin E to PUFA ratio, lower serum cholesterol, and are 
hydrolyzed more rapidly, but they may not be as effective in promoting 
protein accretion [64].
A 20% IV fat emulsion is typically started at 0.5-1 g fat/kg on the first 
day of life generally at the same time amino acids are started to prevent 
the occurrence of essential fatty acid deficiency as well as to provide 
a more generous source of calories. The lipid emulsion is advanced as 
tolerated in incremental rates of 0.5-1 g/kg/d to a typical maximum of 
3 g/kg/d [48].
In a balanced PN solution, this generally approximates about 30% of 
total calories from fat. Fluid-restricted, growth-compromised patients 
or those limited to peripheral line access may require as high as 
3.5-4 g fat/kg/d to achieve adequate energy for growth and protein 
Nutrient additive Usual daily requirements in PN
Manganese in PTE Withhold during the first 2 weeks of PN
Decrease amount or withhold with complication of renal dysfunction
Premature: Begin at 0.05 µg/kg/d and advance to 0.05-0.2 µg/kg/d
Term: 0.2 µg/kg/d
Iodide (I) Withhold during the first 2 weeks of PN
Decrease amount or withhold with complication of obstructive jaundice
Molybdenum (Mb) Premature: Begin at 0.75 µg/kg/d and advance to 1.0 µg/kg/d
Term: 1.0 µg/kg/d
Iron (Fe) as dextran or ferrous citrate Withhold for the first 3 months of PN
Premature: 1.0 µg/kg/d
Withhold for the first 3 months of PN
Decrease amount or withhold with complication of renal dysfunction
Fluoride (Fl) Premature/term: 0.25 µg/d
May withhold until 2 months of age (premature), 3 months of age (term) and considered
for infants who do not receive regular blood transfusions.
Premature/term: 1.0-2.0 µg/kg/d
Withhold for the first 3 months of PN then provide premature with 500 µg/kg/d
Solutions may be contaminated with fluoride
PN: Parenteral nutrition, PTE: Pediatric trace element, MVI: Multivitamin for infusion, ELBW: Extremely low in birth weight
Table 2: (Continued)
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sparing. This intake is appropriate as long as the fat intake remains 
<60% of nonprotein calories. In neonates, the maximal removal 
capacity of plasma lipids was shown to be 0.3 g/kg/hr. To minimize the 
occurrence of hyperlipemia, bilirubin displacement, and respiratory 
compromise, lipid infusion rates ≤0.15 g/kg/hrs are recommended 
to span over 24 hrs. The delivery of 3 g/kg/d of a 20% lipid emulsion 
equates to an infusion rate of 0.125 g/kg/hr [48,65].
Premature infants have limited fat stores and lipoprotein lipase 
concentrations that may hinder their ability to clear plasma lipids 
following infusions of IV fat [15]. The use of heparin dosing at 
0.5-1 units/mL of total parenteral nutrition solutions, with a maximum 
of 137 units/d, can facilitate lipoprotein lipase activity to help stabilize 
serum TG values [43,64].
Lipids may be restricted in patients with hyperbilirubinemia in 
minimum amounts that will provide only the essential fatty acids. 
Some clinicians will reduce or withhold lipids if rising bilirubin trends 
approach levels requiring exchange transfusions. Because both lipids 
and bilirubin are transported in the blood by albumin, lipids competing 
for binding sites on albumin may result in insufficient binding of 
bilirubin to facilitate excretion [49]. Persistently, high bilirubin values 
may increase the risk of kernicterus from the deposition of bilirubin 
in brain cells. A free fatty acid to albumin ratio (FFA: Albumin) >6:1 is 
thought to be clinically significant [57,67].
Micronutrients
Electrolytes
Sodium, potassium, and chloride are essential to life and requirements 
are dependent on obligatory losses, abnormal losses, and amounts 
necessary for growth. Estimated and advisable intakes are based on 
accretion studies and urinary and fecal losses from balance studies 
completed in the late 1970s [26]. Sodium and potassium can be given 
as chloride, lactate, or phosphate salts. Infants who receive electrolytes 
solely as chloride salts may develop hyperchloremic metabolic acidosis. 
Sodium can also be given as acetate; a randomized trial in 1997 
demonstrated the utility of acetate in PN solutions [27]. Potassium is 
added when the urinary flow is established and sodium is added post-
diuresis. Chloride is generally given as sodium chloride. Thorough 
and up-to-date discussions of fluid and electrolyte management of 
premature infants are published elsewhere [26,28].
Major minerals
Calcium, phosphorus, and magnesium are the most abundant minerals 
in the body. They are closely interrelated to each other in metabolism, 
the formation of tissue structure, and function. Amounts of calcium 
and phosphorus are initiated at maintenance levels and advanced 
when energy and protein intakes are adequate to support intrauterine 
accretion rates of lean tissue [29]. The adequacy of these nutrients from 
PN solutions has been studied extensively in the premature population 
and in-depth discussions appear elsewhere [30,31,68-72].
Trace minerals
Recommended amounts for trace minerals are listed in Table 3. The 
1988 American Society of Clinical Nutrition (ASCN) guidelines [73] 
are given for term and preterm infants and compared with the 
1993 consensus recommendations of an international panel of 
experts for preterm infants that are defined as transitional (within 
the first 2 weeks’ of life) and stable (after 2 weeks’ of age) [74]. 
Zincis universally recommended from day one of PN, whereas the 
other trace minerals are generally provided after 2, 4, or 12 weeks’ 
of PN without any appreciable enteral feeding. Copper, selenium, 
molybdenum, and iron can be delivered separately also. Several 
trace element solutions are available with varying combinations of 
zinc, copper, chromium, manganese, and/or selenium [31]. Copper 
and manganese are discontinued from PN solutions with the 
complication of cholestasis, and amounts of chromium, selenium, 
and molybdenum are reduced or omitted when renal output is 
low [73]. Many of the component solutions to PN are found to be 
“contaminated” with trace elements, and therefore, administration 
before actual need may increase risk for toxicity [52,75-78]. Some 
have suggested copper requirements greater than the 20 µg/kg/d 
recommendation [30,73,74,79].
Because of the oxidant effect of copper as well as the risk of toxicity 
from limited excretion in patients with cholestasis, Greene et al. [73] 
advise the lower amount. Minimal enteral feedings are also a source 
of copper within the first 2 weeks. Although they may cause allergic 
reactions, iron dextran and ferrous citrate can be used to supplement 
PN solutions. Parenteral iron supplementation may be delayed until 
2 months of age in premature infants and 3 months of age in term infants 
and considered for those infants who do not receive regular blood 
transfusions [31]. Concern for iron overload is related to increased risk 
for septicemia in malnourished infants with a low serum transferrin 
as well as an increased need for vitamin E [31,73,80]. Even though 
recommendations for premature infants exist within the first 2 weeks 
of life for copper, selenium, chromium, iron, iodide, and manganese, 
these trace minerals generally are not added to PN but are provided 
within minimal enteral feedings. Supplementation with iodide may 
not be necessary because needs for iodide may be met from the topical 
absorption of iodide-containing disinfectants, detergents, and other 
environmental sources [73].
Table 3: Amounts of trace minerals recommended for term and preterm infants in PNa
Trace 
elements
Term (µg/kg/d) Preterm (µg/kg/d) ASCN (1998)
Consensus recommendations (1993)
ASCN (1988) Transitional (first 2 weeks of life) Stable (>2 weeks old)
Chromiumb
Copperc, d 0.20 0-0.05 0.05-0.2 0.2
Irone 20 0-20 20 20
Flouridef - 0-200 100-200 -
Iodide - - -
Manganesec 1.0 1.0 1.0 1.0
Molybdenumb 1.0 0-0.75 1.0 1.0
Seleniumb 0.25 0 0.25 0.25
Zincg 2.0 0-1.3 1.5-2.0 2.0
250 150 400 400
aReprinted with permission from Denne et al. [34] Recommendations are those from the ASCN, subcommittee on pediatric PN requirements, from the Committee 
on Clinical Practice Issues, 1988, 25 and Greene et al. [74]. bRenal dysfunction can cause toxicity. cImpaired biliary excretion can cause toxicity. dGreater 
amount (40 µg/kg/d) is suggested for very low in birth weight infants without cholestasis. eEstimated daily IV requirement is 100 µg/kg for term infants and 200 µg/kg 
for preterm infants. fOnly consider with PN longer than 3 months as solutions may be contaminated with fluoride; a dosage of 500 µg/kg/day for preterm infants. gThe 
only trace element recommended on day 1 of TPN. When TPN is required_3 months, decrease dosage to 100 µg/kg/d. PN: Parenteral nutrition, ASCN: American Society 
of Clinical Nutrition
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Vitamins
The most recent guidelines for parenteral vitamin administration for 
infants remain those published as the consensus recommendations 
from an international panel of experts in 1993 [74]. These are compared 
in Table 4 to those recommended in 1988 by the ASCN [73]. For the most 
part, recommended intakes are based on serum vitamin concentrations 
measured in term and preterm infants who received various amounts 
of different vitamins [73]. These studies were primarily completed in 
infants >1000 g at birth. Thus, specific needs of ELBW infants remain 
unclear [81]. There commended parenteral vitamin intakes can only be 
approximately delivered from multivitamin for infusion (MVI) pediatric. 
The standard dose of 2 mL/kg/d with a maximum intake of 5 mL/d 
provides lower amounts of vitamin A and higher amounts of most of 
the B vitamins (Table 4). Furthermore, IV vitamin delivery may be less 
due to photodegradation of vitamins A, D, E, K, B2, B6, B12, C, and folic 
acid and adsorption of vitamins A, D, and E into the vinyl delivery bags 
and tubing [43]. Some clinicians have addressed these issues with the 
protection of delivery equipment from light and the administration of 
fat-soluble vitamins with lipid [82,83]. The need for a newly formulated 
pediatric MVI solution that better meets the premature infant’s needs 
has been discussed and recommendations for its composition have 
been suggested [30,73].
COMPLICATIONS ASSOCIATED WITH PN
Complications associated with PN therapy can be categorized into 
mechanical, metabolic, and infectious problems. The pharmacist must 
be aware of these complications and how they are likely to present, 
when they are likely to occur, and what can be done to prevent them.
Mechanical
Mechanical complications are catheter-related and may occur short- 
or long-term. Short-term complications are those related to catheter 
insertion and include pneumothorax, hemothorax, subclavian artery 
injury, air embolism, thoracic duct injury, catheter embolization, and 
catheter malposition [84].
Long-term mechanical complications include catheter occlusion, 
thrombosis, and catheter breakage. Catheter occlusion is the most 
frequent noninfectious mechanical complication seen with the use of 
long-term venous access devices. It may be due to a blood clot, fibrin 
sheath, drug or calcium precipitate, or catheter pinch-off syndrome. 
Occlusion can be prevented by correct catheter position, a routine 
flushing protocol with heparinized saline, monitoring of drug and 
nutrient incompatibilities, and use of in-line filters [85].
Thrombosis development can be promoted by catheter malposition or 
injury to the vein wall during or after catheter insertion, or it can be 
chemically induced. The catheter tip should be positioned at the junction 
of the superior vena cava and the right atrium. Venous thrombosis can 
be manifested by neck or arm swelling or pain. Treatment depends on 
the extent of the thrombus, the need to maintain current access, and 
the severity of symptoms. The conservative approach is to leave the 
catheter in place and to give anticoagulation therapy. Catheter removal 
may be warranted with extended thrombus [86,94].
Metabolic
Metabolic complications are clearly the problem area, in which 
pharmacists can have the most input into prevention and treatment. 
These complications can be categorized as short- and long-term 
issues. In the hospitalized patient, PN is usually infused over 24 hrs, 
and as the patient is transitioning to home or long-term care, the PN 
solution is cycled (given over a shorter period of time such as 6-12 hrs). 
Usually, the infusion rate is increased over the first several hours and 
decreased (tapered) over the last hours of the infusion period. This 
will help temper some of the short-term metabolic complications 
that are described below. Short-term complications include refeeding 
syndrome, hyperglycemia and hypoglycemia, mineral and electrolyte 
imbalances, and hypertriglyceridemia. Most of these can be prevented 
with careful monitoring, proper nutrient dosing, and conformation to 
standard PN labeling guidelines [92].
Refeeding syndrome is one of the most critical complications that 
occur with the initiation of PN. It has been elegantly described 
by Solomon and Kirby [87] and is defined as the metabolic and 
physiologic consequences of the depletion, repletion, compartmental 
shifts, and interrelationships of phosphorus, potassium, magnesium, 
glucose metabolism, vitamin deficiency, and fluid resuscitation. More 
specifically, as an extremely malnourished individual is started on PN, 
cardiopulmonary and neurologic complications may occur as a result 
of hypokalemia, hypophosphatemia, and hypomagnesemia among 
Table 4: Amounts of vitamins recommended for term and preterm infants in PN solutions compared to prescribed dosages of 
MVI‑pediatrica
Vitamin Term (dose/d) Preterm (dose/kg/d)
ASCN (1988) MVI‑pediatric 
(1 vial; 5 ml)
Consensus 
recommendations (1993)
ASCN (1988) MVI‑pediatric 
(40% of vial; 2 ml/kg/d)b
Fat soluble
Vitamin A (IU) 2300 2300 700-1500 1640 920
With lung disease - - 1500-2800 - -
Vitamin D (IU) 400 400 40-160 160 160
Vitamin E (IU) 7.0 7.0 3.5 (max=7) 2.8 2.8
Vitamin K (µg) 200c 200c 6-30 (at birth) 80 80
Water soluble
Vitamin B6 (µg) 1000 1000 150-200 180 400
Vitamin B12 (µg) 1.0 1.0 0.3 0.3 0.4
Vitamin C (mg) 80 80 15-25 25 32
Biotin (µg) 20 20 5-8 6.0 8.0
Folic acid (µg) 140 140 56 56 56
Niacin (mg) 17 17 4.0-6.8 6.8 6.8
Pantothenate (mg) 5.0 5.0 1-2 3.0 2.0
Riboflavin (µg) 1400 1400 150-200 150 560
Thiamin (µg) 1200 1200 200-350 350 480
aReprinted with permission from Denne et al. [34]. Recommendations are those from the American Society of Clinical Nutrition (ASCN), Subcommittee on Pediatric 
PN Requirements, from the Committee on Clinical Practice Issues, 1988, [73] and Greene et al. [74]. Needs of the Preterm Infant: Scientific Basis and Practical 
Guidelines. Baltimore, Williams These recommendations are currently not achievable because no ideal IV vitamin preparation is available for preterm infants; 40% of a 
vial (2 ml/kg/d) of MVI-pediatric (Armor, USA, Rover, Canada) is the closest intake that can be achieved at this time. bMaximum not to exceed a dosage of 5 ml/d. cThis 
does not include the 0.5-1.0 mg of vitamin K given at birth, as recommended by the American Academy of Pediatrics [48]. PN: Parenteral nutrition, ASCN: American 
Society of Clinical Nutrition, MVI: Multivitamin for infusion
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other reasons. Risk factors for refeeding include alcoholism, anorexia 
nervosa, marasmus, rapid refeeding, and excessive dextrose infusion. 
The prevention of refeeding syndrome includes repletion of potassium, 
phosphorus, and magnesium; limiting dextrose dosing initially; limiting 
sodium in early PN solutions [95].
Hyperglycemia is the most common metabolic complication 
associated with PN. Risk factors include metabolic stress, concurrent 
glucocorticoid therapy, diabetes, obesity, sepsis, and excessive dosage 
of glucose. The prevention includes limiting glucose administration 
to 2-3 mg/kg/minutes for at-risk patients, and 5 mg/kg/minutes in 
others, along with monitoring glucose every 6-8 hrs. The treatment 
includes decreasing the glucose dosage, administering regular insulin 
to keep glucose levels from 150 to 200 mg/dl, or both [89,96].
Hypoglycemia occurs most often when PN is suddenly discontinued. 
This can happen with occlusion of the central venous catheter, 
malfunction of the IV pump, or cycling off the PN. It can be prevented 
by slowly tapering the infusion rate and monitoring blood glucose 
concentration 1-2 hrs after the PN is discontinued [97].
Mineral and electrolyte imbalances include elevated or deficient levels 
of sodium, potassium, calcium, magnesium, phosphorus, or chloride. 
The most common imbalances that occur with PN are hyponatremia 
resulting an excess of hypotonic fluid, hypokalemia resulting from 
inadequate potassium intake, intracellular shifts or excessive GI losses, 
hypophosphatemia resulting from inadequate phosphorus intake or 
intracellular shifts, and hypomagnesemia resulting from alcoholism 
and refeeding syndrome. These imbalances can be prevented by 
providing an adequate dose of minerals and electrolytes as suggested 
in the ASPEN safe practices report and providing recommended 
volume requirements of 20-40 ml/kg/day to prevent fluid overload 
or dehydration [92]. The treatment for these imbalances includes 
assessing excess losses and repleting minerals and electrolytes in 
the PN solution when possible (calcium-phosphorus compatibility 
limitations may prevent full repletion via the PN solution) [5].
Hypertriglyceridemia may occur in patients who are unable to 
metabolize the IV lipids. Patients with baseline hypertriglyceridemia 
such as those with sepsis, AIDS, or lipid-induced acute pancreatitis may 
need to have lipid-free or low-dose-lipid PN. Monitoring of the TG level 
elevation over baseline after a low dose of lipids will help gauge whether 
patients must have lipid-free PN or whether a daily, continuous, low-
dose infusion can be tolerated [90].
Long-term metabolic complications include hepatic dysfunction, 
metabolic bone disease, and trace element deficiencies. Hepatic 
dysfunction associated with PN is considered to be of a multifactorial 
nature. Causes include infusion of carbohydrates at an excess of 
5 mg/kg/minutes and sepsis. Steatosis occurs and can cause an 
elevation of transaminases and alkaline phosphatase days to weeks 
after initiation of PN. Elevated bilirubin concentration is seen less often, 
and enzymes lost often return to normal after the PN is discontinued. 
Treatment options include giving at least one-third of calories as lipids, 
cycling PN over 12 hrs to decrease continuously elevated insulin levels, 
and using the GI tract to stimulate bile flow [91,98].
Metabolic bone disease is a well-documented complication of long-term 
PN therapy. It may demonstrate itself as back pain, periarticular bone pain, 
or fracture. Adults may exhibit hypercalcuria due to excessive infusion of 
fluid, sodium, magnesium, phosphate, vitamin D, or amino acids [99].
Trace element deficiencies may occur in patients receiving long-term 
PN. Periodic zinc, chromium, iron, copper, and selenium levels should 
be measured, and these trace elements repleted as necessary [100].
Infectious
Infectious complications can occur anytime during the course of PN 
therapy. The two general sources of these complications are catheter-
related infection and solution-infusate contamination. The risk of 
catheter-related bloodstream infection remains one of the most serious 
complications associated with PN [101]. Temporary or short-term 
central venous catheters account for about 90% of nosocomial blood 
stream infections, and only 10% of infections are from long-term 
devices such as tunneled catheters or implanted reservoirs [102].
Risk factors for catheter-related infection include age ≥60 years, 
increased severity of illness, distant site of infection, skill of inserter, 
use of catheter, and site of catheter placement [103]. The patients can 
also develop local site infections, port pocket infections, or catheter 
tunnel infections without developing a full blood stream infection. 
Signs and symptoms associated with catheter-related sepsis include 
fever, rigors, malaise, defervescence of fever after catheter removal, 
and positive blood cultures [102]. Treatment options include catheter 
removal, antibiotic lock, or delivery of systematic antibiotics via the 
catheter [93]. The prevention of a catheter-related infection can be 
aided by trained personnel with the use of aseptic technique in catheter 
placement and routine site care, flushing protocols, and tubing changes. 
Clinical monitoring for catheter-related infections includes assessing 
the patient’s temperature, complete blood cell count with differential 
count, blood glucose level (sudden hyperglycemia may be an early 
warning sign), and the catheter insertion site [103].
COMPATIBILITY OF PN
The patients receiving PN therapy often required concomitant drug 
therapy. Most patients have adequate venous access or have multiple 
lumen central venous catheters so that mixing medications with the PN 
formulation is not that issue. However, for some patients with limited 
venous access, directly added medications or piggybacking medication 
via a secondary infusion must be considered. The compatibility of these 
medications and other IV solutions is an important concern in delivering 
safe and effective drug and nutritional therapy. IV medications are 
infused most often as separate admixture piggybacked in the PN line. 
However, some medications may be added directly to PN solution 
and administered at the same rate as the PN infusions. Because of the 
potential for ineffective drug therapy or other complication associated 
with physiochemical incompatibility and stability of the PN solution, 
specific criteria should be considered before one add a medication 
directly to PN solution [107].
Since PN is infused intravenously, it is often considered as a vehicle 
for medication administration. Medication may be added to PN 
formulations in an effort to decrease fluid requirements, reduce the need 
for Y-site injections, reduce the possibility of line contamination due to 
manipulation and decrease labor time required for drug administration. 
Although these reasons may seem compelling, the physicochemical 
complexity of PN formulations makes their interactions with parenteral 
medications a very challenging compatibility dilemma [6].
The stability and compatibility of total PN mixtures compounded for 
patients requiring nutritional support is paramount to their safety on 
IV infusion. The most significant pharmaceutical issues associated with 
mixing total PN formulations affecting their safety involve the stability 
of lipid-injectable emulsions and the compatibility of calcium and 
phosphate salts [99].
Drug-nutrient interactions result in derangements in fluid and 
electrolyte homeostasis, changes in vitamin status, and disturbances 
acid-base balance. Recognition of these drug-nutrient interactions may 
assist the clinician to prevent metabolic complications and to achieve 
desired therapeutics outcomes [99,100]. A major disadvantage to the 
use of PN solutions as drug delivery vehicles is the lack of compatibility 
and stability data in the PN solutions that are used commonly in clinical 
practice.
PN and drug therapy
Patients requiring PN suffer from severe functional or anatomical 
failure of the gastrointestinal tract. The decreased intestinal absorption 
affects the fate of xenobiotics like drugs leading to erratic or absent 
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bioavailability. To overcome the lack of IV access and to reduce 
complicated drug treatments the use of a PN admixture as a vehicle for 
drug treatment is attractive. However, admixing of a solubilized drug 
to an All-in-one (AIO) PN must meet good manufacturing practice to 
avoid microbial contamination, to guarantee a defined formulation, 
and to prevent medication errors. It should be also kept in mind that 
the admixing of a drug to PN creates a new formulation with changed 
properties. This may eventually affect both the bioavailability of the 
PN and of the drug. The literature background is sparse. The variety of 
PN regimens and of drug dosages is huge. Therefore, pharmaceutical 
expertise is mandatory for safe and effective treatment [88,101,102].
Incompatibilities and interactions
Incompatibilities include physicochemical reactions occurring in vitro. 
Pharmacological interactions take place in vivo and affect drug action 
(synergy or antagonism, adverse drug reactions). AIO mixtures 
constitute the standard for PN; in the ready to use form they show 
restricted stability and shelf life. The high number of chemically 
reactive components and the oil/water (o/w) emulsion character of 
lipid-containing AIO admixtures represent a most complex vehicle for 
drug admixing [102]. Incompatibilities may result from direct reactions 
between soluble components but also from reactions with the container 
material or with the gas (oxygen) present in the container. These 
physicochemical reactions depend on concentration, temperature, and 
other co-factors such as light exposure and catalysts (trace elements) 
[97,104,105]. When drugs are added via a Y-site infusion or injection, or 
by a three-way-stopcock, except for the exposure time (time-dependent 
reactions), there is no general difference regarding incompatibility 
reactions in this situation (Table 5) [106].
The following aspects of drug admixing to feeds will be considered 
(Fig. 1) [106]:
• Changes of the emulsion character of the PN formulation
• Reaction of the drug formulation with the AIO bag material (ethyl 
vinyl acetate [EVA], polyvinyl chloride [PVC], polyolefin, etc.)
• Reactions with specific nutrients leading to inactivation (oxidation, 
etc.)
• Reactions with components leading to toxicity (e.g., precipitation, 
radical formation).
Emulsion changes
The o/w emulsion of an AIO admixture is stabilized by amphiphilic 
phospholipid emulsifier (lecithin). Stability is also dependent on 
the source of the TGs, the amino acid pattern, the glucose content 
(viscosity), the electrolyte and trace element concentration, and the pH. 
In a pH range of 5-8, the negatively charged phosphate moiety of the 
emulsifier prevents coalescence of the small oil droplets (250-500 nm 
diameter) by electric repulsion [101].
However, this zeta potential is decreased by (polyvalent) cationic 
agents including positively charged drugs (aminoglycosides) or 
divalent cationic drug salts (Ca- or Mg heparin). Reduced repulsion 
forces between the oil droplets eventually lead to irreversible creaming 
and oiling out [1,102,104].
Therefore, drug formulations with a low pH (e.g., midazolam and 
vancomycin) or a very high pH (aciclovir, furosemide, metoclopramide, 
phenytoin, barbiturates, etc.) should not be admixed to lipid-containing 
AIO admixtures without emulsion dispersal testing, e.g., by light 
microscopy. Highly lipophilic drugs (log Poctanol _3) dissolved as 
micelles by amphiphilic solvents like cremophors or tweens may 
also interact with the lipid emulsion. The resulting formulation, 
even when showing increased o/w emulsion stability, may change 
the biodisposition of the drug and of the TGs (FFA release). Similar 
reactions may occur with other lipophilic drugs like paclitaxel or 
amphotericin B showing small therapeutic indices too. The same has to 
be considered for liposomal formulations. Such drug admixing should 
be omitted in the absence of documented effectiveness and safety of 
the treatment [103,106].
Incompatibilities with the bag material
For lipid containing AIO admixtures plastic bag material without 
softeners is mandatory because of their potential extraction by 
lipids, e.g., phthalates from PVC. EVA and polyolefins (multi-layered 
foils) are common container materials without softeners. Significant 
amounts of lipophilic drugs – such as diazepam, nitroglycerine, and 
dihydropyridines - may be absorbed into (PVC) plastic material. 
Protein drugs - such as albumin, insulin, and growth factors - may also 
be adsorbed on the container surface. Therefore, such drugs should 
not be added to large volume parenteral feeds to avoid loss of active 
drug [104,106].
Inactivation of drugs or PN components
PN is not an inert vehicle but contains essential nutrients intended 
to be administered unchanged. The organic nutrients contain 
aldehyde-, OH- or amino-groups (glucose, amino acids) or conjugated 
double bonds (PUFA) prone to chemical reaction with corresponding 
compounds. Such drugs are characterized by reduced stability and a 
high incompatibility profile (e.g., catecholamines). Most short acting 
medications, used especially in Intensive Care Unit, show high chemical 
reactivity. They should not be added to AIO admixtures due to potential 
rapid inactivation [102].
The presence of trace elements such as iron, copper, and selenium may 
even catalyze oxidative or reductive degradation of drugs (epinephrine) 
or nutrients (ascorbic acid). Such reactions are only partly 
accompanied by color changes of the solution (Maillard reaction) and 
are not always detectable by visual inspection. In contrast, ultraviolet 
spectrophotometry may be able to assess such drug inactivation 
because of the specific absorption analysis of the respective compound. 
Chelators included in drug dosage forms for stability reasons may 
interfere with trace element or electrolyte availability (e.g., EDTA in 
propofol formulations) [102,107].
Fig. 1: Incompatibility reactions in parenteral nutrition
Table 5: Incompatibility reactions
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Degradation reactions leading to potential activity
The solubility of drugs very much depends on the pH of the solution 
because of the acid/base character of most drugs (pKa). Variation in 
pH among different producers of the same drug may also be relevant 
and make extrapolation difficult. Weak acids or weak bases need high 
or low pH to form water-soluble salts. When added to a buffered AIO 
admixture, precipitates are formed reducing the drug and/or nutrient 
concentration according the solubility product. Local pH differences 
may even be more pronounced with Y-site or three-way-stopcock 
administration. Precipitates may be harmful or even fatal. An in-
line filter is not always a guarantee of preventing precipitates being 
infused. As an example, Ca phosphate precipitate is formed when the 
solubility product is exceeded. The salt is more soluble in the cold and 
may therefore only precipitate if the PN admixture is warmed up. In 
contrast to binary PN admixtures, lipid-containing AIO admixtures 
cannot be assessed visually and filters of 1.2 mm pore size used for 
lipid emulsion do not eliminate small particles. Therefore, drugs 
dissolved at pH <5 or >7 (alkaloids, virostatic drugs, vancomycin, etc.) 
are a problem in PN admixtures. Lipid peroxidation of PUFA results 
in radical formation, which can be harmful to the patient. Drugs 
sensitive to oxidation/reduction processes may react with PUFA or 
radicals and modulate peroxidation chain reactions. Molecules like 
tricyclic phenothiazenes (chlorpromazine) easily interact with such 
electron transfer processes and are therefore unsuitable for AIO 
admixing [103,107].
Practical guidelines for drug therapy [103,104,106,107]
• Patients with PN should have a multi-lumen catheter for medication 
therapy
• AIO admixtures represent a most complex and reactive vehicle for 
drug admixing not suitable for most drugs (incompatibilities)
• Intermittent IV administration with sufficient rinsing fluid has to be 
preferred to admixing whenever possible
• Pharmaceutical advice from the nutrition team has to be respected 
in every situation where therapeutic drug admixing is necessary
• Physicochemical characterization of the drug formulation is 
a prerequisite to estimate possible compatibility (pH, pKa, 
physicochemical stability of the active ingredient, formulation 
additives, etc.)
• Molar concentration ratios between reaction partners have to be 
considered
• Admixing is possible only immediately before administration at 
maximal dilution
• Check the therapeutic effect of the admixed drug as an indirect 
bioavailability test
• The use of standard PN formulations and standard drug protocols 
will allow the establishment of a data base for reference.
No admixing when:
• Presence of solubilizers to dissolve lipophilic drugs (ethanol, 
cremophor, etc.)
• Drugs with chemical instabilities (lyophilisates)
• Small therapeutic indices of the drug (cytotoxics, etc.)
• Short elimination half-lives of the drug (limited variation in 
administration speed).
Admixing possible when:
• Sufficient stability reported (literature, experimental analysis)
• Drug formulation compatible with pH of AIO admixture
• No ingredients with incompatibilities with AIO admixtures (divalent 
cations)
• Large therapeutic index of the drugs involved (analgesics, sedatives, 
H2-antagonists)
• Aseptic admixing and documented protocol given (pharmacy with 
controlled areas)
• Simple stability testing possible (pH, lipid droplet size analysis, 
inspection for coloration and precipitation)
• In-line filter.
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